Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Pre-treatment Elevated Platelet Count Associates with HER2 Overexpression and Prognosis in Patients with Breast Cancer

  • Gu, Mei-Ling (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) ;
  • Yuan, Cai-Jun (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) ;
  • Liu, Xiao-Mei (Department of Oncology, The First Affiliated Hospital of Liaoning Medical University) ;
  • Zhou, Yi-Chao (Department of Breast Surgery, The First Affiliated Hospital of Liaoning Medical University) ;
  • Di, Shu-Huan (Department of Laboratory, The First Affiliated Hospital of Liaoning Medical University) ;
  • Sun, Fei-Fei (Department of Pathology, The First Affiliated Hospital of Liaoning Medical University) ;
  • Qu, Quan-Ying (Department of Epidemiology, Liaoning Medical University)
  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To research the association between pre-treatment elevated platelet count and clinicopathologic characteristics in breast cancer (BC), as well as explore the relationship between pre-treatment elevated platelet count and HER2 status and prognosis of BC patients. Materials and Methods: A retrospective cohort of BC patients who were newly diagnosed or treated by surgery only and had pathological detection results and platelet values in the Department of Oncology, the First Affiliated Hospital of Liaoning Medical College were enrolled from 1/1/2008 until 31/12/2009, and followed up until 31/12/2014. Age, thrombocyte parameters before chemotherapy and/or radiotherapy, immunohistochemical (IHM) indexes, and regional lymph node (LN) involvement and progression-free survival (PFS) were recorded. Results: A total of 447 eligible subjects were included in this research. As we analyzed, for HER2, positive and negative, the incidence rates of elevated platelet count were 25.8% and 14.7% (P<0.05). In the Cox proportional hazards model both variables were independent risk factors for BC (for HER2, OR, 0.592, 95% confidence interval, CI, 0.355 to 0.985, P=0.044;f or PLT, OR, 0.998, 95% CI, 0.996 to 1.000, P=0.042). For ER, PR, Ki67 and LN involvement, the differences were not statistically significant (P>0.05). Conclusions: In this research, pre-treatment elevated level of platelet count demostrated a significantrelationship with HER2 amplification/overexpression, and both variables significantly influenced the prognosis of BC. However, elevated platelet count did not exhibit any association with ER, PR, Ki67 and LN involvement.

Keywords

References

  1. Bewick V, Cheek L, Ball J (2004). Statistics review 13: receiver operating characteristic curves. Crit Care, 8, 508-12. https://doi.org/10.1186/cc3000
  2. Buergy D, Wenz F, Groden C, Brockmann MA (2012). Tumorplatelet interaction in solid tumors. Int J Cancer, 130, 2747-60. https://doi.org/10.1002/ijc.27441
  3. Burstein HJ (2005). The distinctive nature of HER2-positive breast cancers. N Engl J Med, 353, 1652-4. https://doi.org/10.1056/NEJMp058197
  4. Chen Y, Zhang L, Liu WX, Liu XY. (2015). Prognostic signifiance of preoperative anemia, leukocytosis and thrombocytosis in Chinese women with epithelial ovarian cancer. Asian Pac J Cancer Prev, 16, 933-9. https://doi.org/10.7314/APJCP.2015.16.3.933
  5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, J Godwin, R Gray, et al (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378, 771-84. https://doi.org/10.1016/S0140-6736(11)60993-8
  6. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME (1999). Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol, 70, 6-12. https://doi.org/10.1002/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.0.CO;2-X
  7. Fang-Xuan Li, Li-Juan Wei, Huan Zhang, Shi-Xia Li, Jun-Tian Liu (2014). Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer. Asian Pac J Cancer Prev, 15, 6511-7. https://doi.org/10.7314/APJCP.2014.15.16.6511
  8. Foy KC, Miller MJ, Moldovan N (2012). Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology, 1, 1004-16. https://doi.org/10.4161/onci.21057
  9. Gastl G, Plante M, Finstad CL, et al (1993). High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol, 83, 433-41. https://doi.org/10.1111/j.1365-2141.1993.tb04668.x
  10. Gerdes J, Schwab U, Lemke H, Stein H (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, 13-20. https://doi.org/10.1002/ijc.2910310104
  11. Gown AM (2008). Current issues in ER and HER-2 testing by IHC in breast cancer. Mod Pathol, 21, 8-15. https://doi.org/10.1038/modpathol.2008.34
  12. Ikeda M, Furukawa H, Imamura H, et al (2002). Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol, 9, 287-91. https://doi.org/10.1007/BF02573067
  13. International Breast Cancer Study Group. Colleoni M, Gelber S, Goldhirsch A, et al (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer: international breast cancer study group trial 13-93. J Clin Oncol, 24, 1332-41. https://doi.org/10.1200/JCO.2005.03.0783
  14. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001). HER2 (neu) signaling increases the rate ofhypoxia-inducible factor 1 (HIF-1) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol, 21, 3995-4004. https://doi.org/10.1128/MCB.21.12.3995-4004.2001
  15. Li Y, Miao LY, Xiao YL, Cai HR, Zhang DP (2014). Elevated platelets enhance cancer cell migration,promote hematogenous metastasis and associate with a poor prognosis in advanced non-small cell lung cancer cases. Asian Pac J Cancer Prev, 15, 139-43. https://doi.org/10.7314/APJCP.2014.15.1.139
  16. Monreal M, Fernandez-Llamazares J, Pinol M, et al (1998). Platelet count and survival in patients with colorectal cancer-a preliminary study. Thromb Haemost, 79, 916-8.
  17. Nakano T, Chahinian AP, Shinjo M, et al (1998). Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer, 77, 907-12. https://doi.org/10.1038/bjc.1998.150
  18. O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL (1999). Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, 353, 1494-5.
  19. O'Byrne KJ, Dobbs N, Propper D, Smith K, Harris AL (1999). Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet, 353, 1494-5.
  20. Olesen LL, Thorshauge H (1988). Thrombocytosis in patients with malignant pleural mesothelioma. Cancer, 62, 1194-6. https://doi.org/10.1002/1097-0142(19880915)62:6<1194::AID-CNCR2820620625>3.0.CO;2-M
  21. Pathmanathan N, Balleine RL, Jayasinghe UW, et al (2014). The prognostic value ofKi67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol, 67, 222-8. https://doi.org/10.1136/jclinpath-2013-201793
  22. Pedersen LM, Milman N (1996). Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J, 9, 1826-30. https://doi.org/10.1183/09031936.96.09091826
  23. Puhalla S, Brufsky A (2013). Treatment of HER2-positive breast cancer:looking backwards briefly. Lancet Oncol, 14, 1250-1. https://doi.org/10.1016/S1470-2045(13)70536-9
  24. Ramirez A, Boulaiz H, Morata-Tarifa C, et al (2014). HER2-signaling pathway, JNK and ERKs kinases, and cancer stemlike cells are targets of Bozepinib. Onco Target, 5, 3590-606.
  25. Stravodimou A,Voutsadakis IA (2013). Pretreatment Thrombocytosis As A Prognostic Factor In Metastatic Breast Cancer. Int J Breast Cancer, 2013, 289563-8.
  26. Taucher S, Salat A, Gnant M, et al (2003). Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost, 89, 1098-106.
  27. Verheul HM, Hoekman K, Luykx-de Bakker S, et al (1997). Platelet:transporter ofvascular endothelial growth factor. Clin Cancer Res, 3, 2187-90.

Cited by

  1. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: a Meta-analysis vol.6, pp.1, 2016, https://doi.org/10.1038/srep23262
  2. The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: a systematic review and meta-analysis vol.11, pp.2, 2017, https://doi.org/10.2217/bmm-2016-0214
  3. Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program vol.13, pp.1, 2018, https://doi.org/10.1007/s11523-017-0542-1